Navigation Links
SureGene and PGXL Laboratories launch the SureGene Test for Antipsychotic and Antidepressant Response (STA2R)
Date:8/29/2012

LOUISVILLE, Ky., Aug. 29, 2012 /PRNewswire/ -- SureGene announced today that it has partnered with PGXL Laboratories, a CLIA-certified lab in Louisville, KY., to launch the SureGene Test for Antipsychotic and Antidepressant Response (STA2R), a breakthrough pharmacogenetic test containing genetic markers for effectiveness of antipsychotic drug treatment.  STA2R provides clinicians with valuable new information to facilitate personalized antipsychotic and antidepressant drug selection.

Millions of people each year are treated with antipsychotic drugs, and tens of millions are treated with antidepressants.  Very often, patients must try several drugs before finding the right one for them.  With the STA2R report, for the first time clinicians have useful medical information to augment their experience for selecting a drug treatment for each patient.

STA2R combines the propriety SULT4A1-1 genetic signature with four other gene tests. Clinical studies in Caucasian schizophrenic patients have indicated that SULT4A1-1 positive patients treated with olanzapine have greater reduction in psychotic symptoms and a significantly lower risk of being hospitalized.  Additionally STA2R helps identify those patients for whom risperidone, the current standard treatment, is contraindicated and patients that may not respond as well to certain antidepressants.

"STA2R represents a revolutionary change to the treatment of schizophrenia and bipolar disorder.  For the first time, physicians will have a test that can help them prioritize the treatment choices for their patients," say Dr. Bill W. Massey, President of SureGene.

STA2R has an easy collection process requiring only a simple cheek swab in the healthcare professional's office.  The swabs are then placed in the pre-paid shipping container, which is then delivered to PGXL Laboratories, a CLIA-certified lab in Louisville, KY.  Within a few days, the clinician receives a secure report.

SureGene discovered and patented the SULT4A1 genetic signature.  PGXL Laboratories independently developed the STA2R test and will exclusively perform the test in its laboratory.  SureGene is working with healthcare providers to promote the test.

About STA2R report:  The SureGene Test for Antipsychotic and Antidepressant Response (STA2R) is a panel of genetic tests that gives prescribers additional information upon which to base medication selection. The test provides information regarding the potential response of individual patients to antipsychotic and antidepressant treatment based upon the information known about their genetic makeup. This information covers three areas: clinical response, adverse event liability, and drug metabolism. Currently, the test provides detailed information for the most widely used atypical antipsychotics and antidepressants. While the test report describes the patient's most likely response to the listed drugs, every patient is unique and not all patients will respond in a typical fashion.

About SureGene:  SureGene, LLC, provides personalized solutions for the treatment of serious mental illnesses. SureGene discovers and develops personalized medicine tests that deliver exceptional clinical utility to address the high level of unmet medical need for the treatment of schizophrenia and bipolar disorder.

About PGXL Laboratories:  A privately-owned business located in Louisville, Kentucky, PGXL Laboratories was the first lab in the country CLIA-certified specifically to conduct pharmacogenetic tests. It offers pharmacogenetic testing, interpretive services, and assay design and validation. Along with its clinical practice, PGXL performs contract research for developers of pharmaceuticals and medical equipment.

For more information about STA2R please visit www.suregenetest.com.


'/>"/>
SOURCE SureGene, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
2. Use Notebook Studies to Ensure Successful Reusable Device Cleaning Validations, Recommends Microtest Laboratories
3. BD and PEPFAR Launch Labs for Life to Strengthen Laboratories in Regions Heavily Burdened by Disease
4. Carl Icahn Issues Open Letter to Shareholders of Forest Laboratories
5. Medica Announces Global Release of the EasyCell Assistant Analyzer for Hematology Laboratories
6. RoundTable Healthcare Partners Portfolio Company, Renaissance Acquisition Holdings, LLC Acquires DPT Laboratories
7. Carl Icahn Issues Letter To Howard Solomon Of Forest Laboratories
8. Millennium Laboratories Wins Lawsuit: Ameritox Advertisements Regarding Rx Guardian and Rx Guardian CD Contain Literally False Statements
9. Court Preliminarily Deems Millennium Laboratories Press Release Misleading
10. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
11. PeaceHealth Laboratories New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017 Under the impetus ... packaging market size increased year by year at ... to 2021, the market size will maintain the ... to outnumber RMB140 billion in 2021, thanks to ... development of biological agents and supporting policies. ...
(Date:3/22/2017)... March 22, 2017 New Jersey,s ... of patient harm and saved $641 million in healthcare ... in a national quality improvement program. ... for Patients-New Jersey, part of a national initiative from ... selected the New Jersey Hospital Association and its affiliate, ...
(Date:3/22/2017)... Mar 22, 2017 Research and Markets ... Point Inhibitors Market & Clinical Pipeline Insight 2022" drug ... ... & Clinical Pipeline Insight 2022 report gives comprehensive insight on ... of immune check point inhibitors as main streamline drugs in ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... ... An intensive search of the medical literature has revealed no research yet on ... He says investigating this possibility, is important because Miami-Dade in 2016 led the U.S. ... , His findings appear on Analizir.com. . Dr. Norins, who trained ...
(Date:3/22/2017)... , ... March 22, 2017 , ... Last year, 43 ... a US Department of Agriculture report. While excess dairy can be caused by ... role. Lactose sensitivity is the inability to properly digest lactose, a sugar found in ...
(Date:3/22/2017)... ... 22, 2017 , ... The Vanderbeck Agency, a Long Island firm providing insurance, ... embarking on a combined charity effort with the Great Neck Breast Cancer Coalition to ... the Great Neck Breast Cancer Coalition has worked to support breast cancer patients in ...
(Date:3/22/2017)... ... 2017 , ... The Zabbia Insurance Agency, a Long Island ... owners in the greater Nassau County area, is embarking on a cancer awareness ... minutes, someone in America is diagnosed with blood cancer. Every 9 minutes, someone ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Senior Citizens League (TSCL) is ... default on the federal debt — including the debt held by the Social Security ... said TSCL in a letter to House and Senate budget leaders. “In prior ...
Breaking Medicine News(10 mins):